Lupus erythematosus: systemic and cutaneous manifestations
N Rothfield, RD Sontheimer, M Bernstein - Clinics in dermatology, 2006 - Elsevier
… Author, Naomi Rothfield treats patients with rising anti-DNA levels associated with falling
complement levels with an increased dose of prednisone because of experience with onset of …
complement levels with an increased dose of prednisone because of experience with onset of …
The 1982 revised criteria for the classification of systemic lupus erythematosus
…, NF Rothfield, JG Schaller, N Talal… - … : Official Journal of …, 1982 - Wiley Online Library
… Lie TH, Rothfield NF: An evaluation of the preliminary criteria for the diagnosis of systemic
lupus erythematosus. Arthritis Rheum 15532-534, 1972 3. Davis P, Atkins B, Josse RG, …
lupus erythematosus. Arthritis Rheum 15532-534, 1972 3. Davis P, Atkins B, Josse RG, …
[HTML][HTML] Cyclophosphamide versus placebo in scleroderma lung disease
…, M Olman, B Fessler, N Rothfield… - … England Journal of …, 2006 - Mass Medical Soc
Background We conducted a double-blind, randomized, placebo-controlled trial to determine
the effects of oral cyclophosphamide on lung function and health-related symptoms in …
the effects of oral cyclophosphamide on lung function and health-related symptoms in …
Range of antinuclear antibodies in “healthy” individuals
…, RN Maini, JS McDougal, NF Rothfield… - … : Official Journal of …, 1997 - Wiley Online Library
Objective. To determine the range of antinuclear antibodies (ANA) in “healthy” individuals
compared with that in patients with systemic lupus erythematosus (SLE), systemic sclerosis (…
compared with that in patients with systemic lupus erythematosus (SLE), systemic sclerosis (…
Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma
WC Earnshaw, N Rothfield - Chromosoma, 1985 - Springer
We have examined “preimmune” serum samples from a patient who progressively developed
the symptoms of scleroderma CREST over a period of several years. During this period, …
the symptoms of scleroderma CREST over a period of several years. During this period, …
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
…, N Rothfield, M Metersky, D Khanna, N Li… - American journal of …, 2007 - atsjournals.org
Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related
interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although …
interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although …
Molecular cloning of cDNA for CENP-B, the major human centromere autoantigen
…, DA Kaiser, TD Pollard, NF Rothfield… - The Journal of cell …, 1987 - rupress.org
… Earnshaw, WC, and NF Rothfield. 1985. Identification of a family of human centromere …
Marino, and NF Rothfield. 1986. Three human chromosomal autoantigens are recognized …
Marino, and NF Rothfield. 1986. Three human chromosomal autoantigens are recognized …
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon
…, ME Csuka, TA Medsger Jr, NF Rothfield… - Arthritis & …, 2002 - Wiley Online Library
Objective To document disease activity and functional status in patients with scleroderma (systemic
sclerosis [SSc]) and Raynaud's phenomenon (RP) and to determine the sensitivity to …
sclerosis [SSc]) and Raynaud's phenomenon (RP) and to determine the sensitivity to …
CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate
…, CA Cooke, H Ratrie III, M Maurer, NF Rothfield… - Cell, 1992 - cell.com
We have isolated and characterized a set of overlap ping cDNA clones that encode the human
centromere autoantigen centromere protein C (CENP-C). The identity of these clones has …
centromere autoantigen centromere protein C (CENP-C). The identity of these clones has …
[PDF][PDF] Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double‐blind, placebo …
…, A Roman‐Miranda, N Rothfield… - Arthritis & …, 2017 - Wiley Online Library
Objective Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling
without substantial reductions in the number of B cells. The aim of this study was to report …
without substantial reductions in the number of B cells. The aim of this study was to report …